MLLCF - Molecular Partners's DARPin molecules show encouraging preclinical action against COVID-19

Molecular Partners ([[MLLCF]] +3.9%) has announced supportive preclinical data from in vivo assessments of its DARPin candidates targeting SARS-CoV-2.In the five-day experiment, all animals treated with DARPin molecules (MP0420 or MP0423) recovered and survived, while 83% of animals in the placebo group had to be euthanized due to severe disease progression."The clinical efficacy observed in both prophylactic and post exposure settings, especially in the context of the severity of disease displayed by our novel COVID-19 model, holds promise for this class of virus-neutralizing inhibitors in later line settings," said Jakob Trimpert, lead investigator of the study.First-in-human studies for MP0420 are anticipated to begin in November, and clinical studies for the second antiviral candidate, MP0423, are expected to initiate in H1 2021.

For further details see:

Molecular Partners's DARPin molecules show encouraging preclinical action against COVID-19